Heterologous boost vaccines for bacillus Calmette–Guérin prime immunization against tuberculosis

References

• Global tuberculosis control: surveillance, planning, financing. WHO report 2007. Geneva, World Health Organization (WHO/HTM/TB/2007.376).
   Google Scholar
• Xing Z, Santosuosso M, McCormick S et al. Recent advances in the development of adenovirus- and poxvirus-vectored tuberculosis vaccines. Curr. Gene Ther.5, 485–492 (2005).
   PubMed Web of Science ®Google Scholar
• Brewer TF. Preventing tuberculosis with bacillus Calmette–Guérin vaccine: a meta-analysis of the literature. Clin. Infect. Dis.31, S64–S67 (2000).
   PubMed Web of Science ®Google Scholar
• McShane H, Hill A. Prime–boost immunisation strategies for tuberculosis Microbes Infect.7, 962–967 (2005).
   PubMed Web of Science ®Google Scholar
• Skeiky YAW, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat. Rev. Microbiol.4, 469–476 (2006).
   PubMed Web of Science ®Google Scholar
• Wang J, Xing Z. Tuberculosis vaccines: the past, present, and future. Expert Rev. Vaccines1, 341–354 (2002).
   PubMedGoogle Scholar
• Orme IM. Tuberculosis vaccines: current progress. Drugs65, 2437–2444 (2005).
   PubMed Web of Science ®Google Scholar
• Aronson NE, Santosham M, Comstock GW et al. Long term efficacy of BCG vaccine in American Indians and Alaska natives: a 60-year follow up study. JAMA291, 2086–2091 (2004).
   PubMed Web of Science ®Google Scholar
• Horwitz MA, Harth G. A new vaccine against tuberculosis affords greater survival after challenge than current vaccine in the guinea pig model of pulmonary tuberculosis. Infect. Immun.71, 1672–1679 (2003).
   PubMed Web of Science ®Google Scholar
• Brandt L, Skeiky YAW, Alderson MA et al. The protective effect on the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect. Immun.72, 6622–6632 (2004).
   PubMed Web of Science ®Google Scholar
• Wedlock DN, Denis M, Skinner MA et al. Vaccination of cattle with a CpG oligodeoxynycleotide-formulated mycobacterial protein vaccine and Mycobacterium bovis BCG induces levels of protection against bovine tuberculosis superior to those induced by vaccination with BCG alone. Infect. Immun.73, 3540–3546 (2005).
   PubMed Web of Science ®Google Scholar
• Kallenius G, Pawlowski A, Brandtzaeg P, Svenson S. Should a new tuberculosis vaccine be administered intranasally? Tuberculosis (Edinb.)87(4) 257–66 (2007).
   PubMed Web of Science ®Google Scholar
• Wang J, Thorson L, Stokes RW et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol.173, 6357–6365 (2004).
   PubMed Web of Science ®Google Scholar
• Santosuosso M, Zhang X, McCormick S, Wang J, Hitt M, Xing Z. Mechanisms of mucosal and parenteral tuberculosis vaccines: adenoviral based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen. J. Immunol.174, 7986–7994 (2005).
   PubMed Web of Science ®Google Scholar
• Santosuosso M, McCormick S, Roediger E et al. Mucosal luminal manipulation of T cell geography switches on protective efficacy by otherwise ineffective parenteral genetic immunization. J. Immunol.178, 2387–2395 (2007).
   PubMed Web of Science ®Google Scholar
• Colditz GA, Brewer TF, Berkey CS et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meat-analysis of the published literature. JAMA271, 698–702 (1994).
   PubMed Web of Science ®Google Scholar
• Colditz GA, Berkey CS, Mosteller F et al. The efficacy of bacilli-Calmette Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics.96, 29–35 (1995).
   PubMed Web of Science ®Google Scholar
• Sterne JA, Rodriguez LC, Guedes IN. Does the efficacy of BCG decline with time since vaccination? Int. J. Tuberc. Lung. Dis.2, 200–207 (1998).
   PubMed Web of Science ®Google Scholar
• Corner LA, Buddle BM, Pfeiffer DU, Morris RS. Vaccination of the brushtail possum (Trichosurus vulpecula) against Mycobacterium bovis infection with bacille Calmette–Guerin: the response to multiple doses. Vet. Microbiol.84, 327–336 (2002).
   PubMed Web of Science ®Google Scholar
• Feng CG, Palendira U, Demangel C, Spratt JM, Malin AS, Britton WJ. Priming by DNA immunization augments protective efficacy of Mycobacterium bovis bacille Calmette-Guerin against tuberculosis. Infect. Immun.69, 4174–4176 (2001).
   PubMed Web of Science ®Google Scholar
• Santosuosso M, McCormick S, Zhang X, Zganiacz A, Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parental Mycobacerium bovis BCG immunization against pulmonary tuberculosis. Infect. Immun.74, 4634–4643 (2006).
   PubMed Web of Science ®Google Scholar
• Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AVS. Enhanced immunogenecity and protective efficacy against Mycobacterium tuberculosis of bacilli Calmette–Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol.171, 1602–1609 (2003).
   PubMed Web of Science ®Google Scholar
• Buddle BM, Wedlock DN, Parlane NA, Corner LAL, de Lisle GW, Skinner MA. Revaccination of neonatal calves with Mycobacterium bovis BCG reduces the level of protection against bovine tuberculosis induced by a single vaccination. Infect. Immun.71, 6411–6419 (2003).
   PubMed Web of Science ®Google Scholar
• Karonga Prevention Trial Group. Randomized control trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet348, 17–24 (1996).
   PubMed Web of Science ®Google Scholar
• Rodrrigues LC, Pereira SM, Cunha SS et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomized trial. Lancet366, 1290–1295 (2005).
   PubMed Web of Science ®Google Scholar
• Tala-Heikkila MM, Tuominen JE, Tala EOJ. Bacillus Calmette–Guérin revaccination questionable with low tuberculosis incidence. Am. J. Respir. Crit. Care Med.157, 1324–1327 (1998).
   PubMed Web of Science ®Google Scholar
• Kubit S, Czajka S, Olakowoski T, Piasecki Z. Evaluation of the effectiveness of BCG vaccinations. Ped. Pol.58, 775–782 (1983).
   PubMedGoogle Scholar
• Lugosi L. Analysis of the efficacy of mass BCG vaccination from 1959–1983 in tuberculosis control in Hungary: multiple comparison of results. Bull. Int. Union Tuberc. Lung Dis.62, 15–34 (1987).
   PubMedGoogle Scholar
• Brandt L, Cunha JF, Olsen AW et al. Failure of Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun.70, 672–678 (2002).
   PubMed Web of Science ®Google Scholar
• Kaufmann SHE. How can immunology contribute to control of tuberculosis. Nat. Rev. Immunol.1, 20–30 (2001).
   PubMed Web of Science ®Google Scholar
• Agger EM, Andersen P. Tuberculosis vaccine subunit development: on the role of interferon-γ. Vaccine19, 2298–2302 (2001).
   PubMed Web of Science ®Google Scholar
• Reed S, Lobet Y. Tuberculosis vaccine development: from mouse to man. Microbes Infect.7, 922–931 (2005).
   PubMed Web of Science ®Google Scholar
• Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG, Andersen P. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette–Guérin immunity. J. Immunol.177, 6353–6320 (2006).
   PubMed Web of Science ®Google Scholar
• Andersen CS, Dietrich J, Agger EM, Lycke NY, Lovgren K, Andersen P. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect. Immun.75, 408–416 (2007).
   PubMed Web of Science ®Google Scholar
• Brooks JV, Frank AA, Keen MA, Bellisle JT, Orme IM. Boosting vaccine for tuberculosis. Infect. Immun.69, 2714–2717 (2001).
   PubMed Web of Science ®Google Scholar
• Majlessi L, Simsova M, Jarvis Z et al. An increase in antimycobacterial Th1-cell responses by prime–boost protocols of immunization does not enhance protection against tuberculosis. Infect. Immun.74, 2128–2137 (2006).
   PubMed Web of Science ®Google Scholar
• Majlessi L, Brodin P, Brosch R et al. Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. J. Immunol.174, 3570–3579 (2005).
   PubMed Web of Science ®Google Scholar
• Pym A, Brodin SP, Majlessi L et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat. Med.9, 533–539 (2003).
   PubMed Web of Science ®Google Scholar
• McMurray DN. Determinants of vaccine-induced resistance in animal models of pulmonary tuberculosis. Scand. J. Infect. Dis.33, 175–178 (2001).
   PubMed Web of Science ®Google Scholar
• Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein. Infect. Immun.73, 4676–4683 (2005).
   PubMed Web of Science ®Google Scholar
• Williams A, Hatch GJ, Clark SO et al. Evaluation of vaccines in the EU TB Vaccine Cluster using guinea pig aerosol infection model of tuberculosis. Tuberculosis85, 29–38 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang X, Divangahi M, Ngai P et al. Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene. Vaccine251342–1352 (2007).
   PubMed Web of Science ®Google Scholar
• Huygen K. On the use of DNA vaccines for the prophylaxis of mycobacterial diseases. Infect. Immun.71, 1613–1621 (2003).
   PubMed Web of Science ®Google Scholar
• D’Souza S, Rosseels V, Denis O et al. Improved tuberculosis DNA vaccines by formulation in cationic lipids. Infect. Immun.70, 3681–3688 (2002).
   PubMed Web of Science ®Google Scholar
• Mollenkopf HJ, Grode L, Mattow J et al. Application of mycobacterial proteomics to vaccine design: improved protection to Mycobacterium bovis BCG prime–Rv3407 DNA boost vaccination against tuberculosis. Infect. Immun.72, 6471–6479 (2004).
   PubMed Web of Science ®Google Scholar
• Derrick SC, Yang AL, Morris SL. A polyvalent DNA vaccine expressing an ESAT6–Ag85B fusion protein protects mice against a primary infection with Mycobacerium tuberculosis and boosts BCG-induced protective immunity. Vaccine23, 780–788 (2004).
   PubMed Web of Science ®Google Scholar
• Romano M, D’Souza S, Adnet PY et al. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacerium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine24, 3353–3364 (2006).
   PubMed Web of Science ®Google Scholar
• Ghosh SS, Gopinath P, Ramesh A. Adenoviral vectors: a promising tool for gene therapy. Appl. Biochem. Biotechnol.133, 9–29. (2006).
   PubMed Web of Science ®Google Scholar
• Xing Z, Braciak T, Ohkawara Y et al. Gene transfer for cytokine functional studies in the lung: the multifunctional role of GM-CSF in pulmonary inflammation. J. Leukoc. Biol.59, 481–488 (1996).
   PubMed Web of Science ®Google Scholar
• Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol. Ther.10, 616–29. (2004)
   PubMed Web of Science ®Google Scholar
• Santosuosso M, McCormick S, Xing Z. Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol.18, 283–91. (2005).
   PubMed Web of Science ®Google Scholar
• Catanzaro AT, Koup RA, Roederer M et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate Vaccine delivered by a replication-defective recombinant adenovirus vector. J. Infect. Dis.194, 1638–49 (2006).
   PubMed Web of Science ®Google Scholar
• Vordermeier HM, Huygen K, Singh M, Hewinson RG, Xing Z. Immune responses induced in cattle by vaccination with a recombinant adenovirus expressing mycobacterial antigen 85A and Mycobacterium bovis BCG. Infect. Immun.74, 1416–1418 (2006).
   PubMed Web of Science ®Google Scholar
• McShane H, Pathan AA, Sander CR et al. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb.)85, 47–52 (2005).
   PubMed Web of Science ®Google Scholar
• Casimiro DR, Chen L, Fu TM et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol.77, 6305–6313 (2003).
   PubMed Web of Science ®Google Scholar
• Williams A, Goonetilleke NP, McShane H et al. Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. Infect. Immun.73, 3814–3816 (2005).
   PubMed Web of Science ®Google Scholar
• Vordermeier HM, Rhodes SG, Dean G et al. Cellular immune responses induced in cattle by heterologous prime–boost vaccination using recombinant viruses and bacille Calmette–Guerin. Immunology.112, 461–470 (2004).
   PubMed Web of Science ®Google Scholar
• McShane H, Pathan AA, Sander CR et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med.10, 1240–1244 (2004).
   PubMed Web of Science ®Google Scholar